Coronavirus company news summary – Sorrento Therapeutics and Mount Sinai’s Icahn School of Medicine collaborate on antibody combinations – Novartis-supported Molecular Therapeutics publish promising interim Phase I results for triple antiviral drug
14 Mar 2021
CollaborateAntibodyVaccine
10 March 2021
Molecular Partners and Novartis announced positive initial results from an ongoing Phase I study of ensovibep, the former’s first tri-specific Covid-19 antiviral treatment, among healthy individuals. Initial findings show the drug was safe and effective; a Phase II/III registrational study is being planned for the second quarter of 2021.
US pharmacy Walgreens has administered approximately five million Covid-19 vaccinations across its stores, long-term care facilities, and through dedicated clinics. The company is supporting vaccination efforts across 43 US states and jurisdictions as part of the Federal Retail Pharmacy Program.
Sorrento Therapeutics announced major progress in developing COVISHIELD antibody combinations through a license agreement with researchers at the Icahn School of Medicine at Mount Sinai. The agreement allows for the collection of antibodies which have the SARS-CoV-2 virus neutralising properties developed by Mount Sinai. This follows on from the success of Sorrento’s intravenous STI-2020 (COVI-AMG) and its intranasal STI-2099 (COVIDROPS).
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.